255 related articles for article (PubMed ID: 29722028)
21. Alpha-synuclein, lipids and Parkinson's disease.
Ruipérez V; Darios F; Davletov B
Prog Lipid Res; 2010 Oct; 49(4):420-8. PubMed ID: 20580911
[TBL] [Abstract][Full Text] [Related]
22. Alpha-Synuclein Nitration and Its Implications in Parkinson's Disease.
He Y; Yu Z; Chen S
ACS Chem Neurosci; 2019 Feb; 10(2):777-782. PubMed ID: 30183251
[TBL] [Abstract][Full Text] [Related]
23. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
[TBL] [Abstract][Full Text] [Related]
24. Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson's Disease.
Boag MK; Roberts A; Uversky VN; Ma L; Richardson DR; Pountney DL
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216492
[TBL] [Abstract][Full Text] [Related]
25. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
26. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
Singh SK; Dutta A; Modi G
Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
[TBL] [Abstract][Full Text] [Related]
27. The link between the gut microbiota and Parkinson's Disease: A systematic mechanism review with focus on α-synuclein transport.
Nielsen SD; Pearson NM; Seidler K
Brain Res; 2021 Oct; 1769():147609. PubMed ID: 34371014
[TBL] [Abstract][Full Text] [Related]
28. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson's disease.
Sian-Hulsmann J; Riederer P
J Neural Transm (Vienna); 2020 May; 127(5):749-754. PubMed ID: 32318880
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?
Pozo Devoto VM; Falzone TL
Dis Model Mech; 2017 Sep; 10(9):1075-1087. PubMed ID: 28883016
[TBL] [Abstract][Full Text] [Related]
30. Fasudil Promotes α-Synuclein Clearance in an AAV-Mediated α-Synuclein Rat Model of Parkinson's Disease by Autophagy Activation.
Yang YJ; Bu LL; Shen C; Ge JJ; He SJ; Yu HL; Tang YL; Jue Z; Sun YM; Yu WB; Zuo CT; Wu JJ; Wang J; Liu FT
J Parkinsons Dis; 2020; 10(3):969-979. PubMed ID: 32568105
[TBL] [Abstract][Full Text] [Related]
31. Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.
Zheng T; Zhang Z
Neurochem Int; 2021 Sep; 148():105094. PubMed ID: 34097990
[TBL] [Abstract][Full Text] [Related]
32. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
33. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
[TBL] [Abstract][Full Text] [Related]
34. Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms.
Chen M; Mor DE
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108366
[TBL] [Abstract][Full Text] [Related]
35. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
[TBL] [Abstract][Full Text] [Related]
36. Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review).
Lei Q; Wu T; Wu J; Hu X; Guan Y; Wang Y; Yan J; Shi G
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34414447
[TBL] [Abstract][Full Text] [Related]
37. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease].
Qiao S; Luo JH; Jin JH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522
[TBL] [Abstract][Full Text] [Related]
38. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
39. Navigating α-Synuclein Aggregation Inhibition: Methods, Mechanisms, and Molecular Targets.
Galkin M; Priss A; Kyriukha Y; Shvadchak V
Chem Rec; 2024 Feb; 24(2):e202300282. PubMed ID: 37919046
[TBL] [Abstract][Full Text] [Related]
40. α-Synuclein Propagation Mouse Models of Parkinson's Disease.
Uemura N; Ueda J; Okuda S; Sawamura M; Takahashi R
Methods Mol Biol; 2021; 2322():119-130. PubMed ID: 34043198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
